Final Results Of Phase I/Ii Trial Of The Oral Mtor Inhibitor Everolimus (Rad001) In Combination With Bortezomib And Rituximab (Rvr) In Relapsed Or Refractory Waldenstrom Macroglobulinemia

Background: Waldenstrom Macroglobulinemia is a distinct lymphoplasmacytic lymphoma. Several clinical trials have shown high rates of response in patients with relapsed WM using bortezomib and rituximab combinations. In addition, the TORC1 inhibitor everolimus has previously shown a high response rate of 70% in this patient population. In this trial, we aimed to examine the safety and activity of the combination of everolimus with bortezomib and rituximab (RVR) and to determine whether a deep response can be achieved with a triple combination of targeted therapeutic agents in WM.